Home › Astrocytoma › Ohio › Columbus
Astrocytoma clinical trials in Columbus, OH
6 studies for Astrocytoma are looking for participants at sites in and around Columbus (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RecruitingPhase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
- Nationwide Children's Hospital, Columbus
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RecruitingPhase 1
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Olutasidenib and Temozolomide in HGG
RecruitingPhase 2
- Nationwide Children's Hospital, Columbus
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RecruitingEarly phase 1Healthy volunteers welcome
- Nationwide Children's Hospital, Columbus
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RecruitingPhase 2
- Nationwide Children's Hospital, Columbus
Astrocytoma trials in other cities
- Houston, TX14 studies
- Boston, MA13 studies
- Chicago, IL9 studies
- New York City, NY9 studies
- Philadelphia, PA7 studies
- Miami, FL7 studies
- Washington, DC6 studies
- Seattle, WA6 studies
- Durham, NC6 studies
- San Francisco, CA6 studies
- Aurora, CO5 studies
- Cincinnati, OH5 studies
Other studies in Columbus
- Non-Small Cell Lung Cancer56 studies
- Breast Cancer39 studies
- Ovarian Cancer39 studies
- Cancer (all types)38 studies
- Lung Cancer37 studies
- Acute Myeloid Leukemia35 studies
- Chronic Lymphocytic Leukemia28 studies
- Metastatic Cancer27 studies
- Endometrial Cancer25 studies
- Colorectal Cancer24 studies
- Prostate Cancer24 studies
- Multiple Myeloma24 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.